Clinical Trial: Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07729332) titled 'Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation' on July 22.

Brief Summary: This study will compare the effect of orforglipron and phentermine on weight maintenance.

Study Start Date: Nov. 01, 2026

Study Type: INTERVENTIONAL

Condition: Obesity

Intervention: DRUG: Phentermine Pill

Phentermine 8 mg or 37.5 mg tablet

DRUG: Orforglipron

orforglipron 0.8, 2.5, 5.5, 9, 14.5 or 17.2 mg tablets

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Massachusetts General Hospital

Information provided by (Responsible Party): Deborah Wexler, MD, Massachusetts General Hospita...